Zota Health Care to acquire 100% stake in Curexis Ventures

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

ZOTA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.2%Reaction day

₹1290.00

prior close

₹1290.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.3%+1.1% vs market

Pharmaceuticals peers, median of 155sector-0.6%+0.4% vs sector

On the reaction day the stock moved 1.1 pts more than Nifty Microcap 250 and 0.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.6

10m

-0.9

15m

-1.1

30m

-0.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.2-1.3+1.1-0.6+0.4

Next day

+0.1+2.4-2.3+1.4-1.4

+3.3+3.8-0.4+1.6+1.8

+0.5+2.7-2.3+0.9-0.4

-0.5+1.9-2.5+0.4-1.0

+3.3+4.6-1.2+2.2+1.2

+8.5+5.1+3.5+2.5+6.1

15d

-0.4+2.1-2.5+0.5-0.9

-6.2-2.1-4.1-1.7-4.5

-14.0-6.4-7.6-6.4-7.6

+3.5+9.5-6.1+3.1+0.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zota Health Care has signed an MOU to acquire 100% stake, equal to 1,00,000 equity shares, in Curexis Ventures Private Limited from its existing shareholders Mr. Sushant Bhattacharya and Mr. Swagato Mukherjee. The goal is to grow the company's footprint in the retail generic pharmacy chain segment. The transaction is classified as a related party deal and will be carried out at arm's length pricing. Financial terms and deal value have not yet been disclosed.

Likely market impact

Strategic move into retail generic pharmacy segment through full acquisition. Expansion focus is positive but deal valuation and integration risks remain unclear.